Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update Aug 14, 2024 4:21pm EDT
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update May 15, 2024 5:11pm EDT
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism Apr 09, 2024 8:11am EDT
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update Mar 29, 2024 8:21am EDT
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement Mar 28, 2024 8:11am EDT
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference Feb 08, 2024 5:55pm EST
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update Nov 13, 2023 4:11pm EST
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors Nov 02, 2023 4:11pm EDT
